Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VRDN
Strong SellSinkerViridian Therapeutics, Inc. · Healthcare · United States · $2.6B · Avg Vol: $34M/d
COMPANY DESCRIPTION
Viridian Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for serious and rare diseases, with a primary emphasis on thyroid eye disease (TED). The company's lead product candidate, VRDN-001, is an anti-IGF-1R antibody designed for rapid and potent efficacy in TED patients. Its focused development strategy targets high unmet medical needs, aiming to capture a significant share of a specialized therapeutic market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.8M | 0.3M | 0.3M | 70.8M | 241.9% | 71.1M | 27.9M | 231.6M | 80.8% |
| EPS | -1.51 | -2.60 | -3.07 | -3.32 | — | -3.40 | -3.95 | -2.77 | — |
| Shares | 110.4M | 110.4M | 81.0M | 101.8M | -7.8% | 113.3M | — | — | — |
| Debt | 5.3M | 21.0M | 21.1M | 50.7M | 112.8% | 244.7M | — | — | — |
| Equity | 395.1M | 442.0M | 671.6M | 722.2M | 22.3% | — | — | — | — |
| Op CF | -93.8M | -184.2M | -232.3M | -276.4M | — | -333.3M | — | — | — |
| Inv CF | -115.1M | -94.3M | -228.7M | -37.6M | — | — | — | — | — |
| Fin CF | 322.2M | 225.7M | 457.7M | 426.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VRDN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VRDN | Viridian Therapeutics, Inc.(you) | $2.6B | 4 | Strong Sell |
| VERA | Vera Therapeutics, Inc. | $2.5B | 5 | Strong Sell |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.5B | 8 | Strong Sell |
| ALMS | Alumis Inc. | $2.9B | 9 | Strong Sell |
| GENB | Generate Biomedicines, Inc. | $2.0B | 6 | Strong Sell |
| KOD | Kodiak Sciences Inc. | $2.4B | 12 | Strong Sell |
| NTLA | Intellia Therapeutics, Inc. | $1.8B | 7 | Strong Sell |
| SNDX | Syndax Pharmaceuticals, Inc. | $1.7B | 6 | Strong Sell |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.1B | 11 | Strong Sell |
| BEAM | Beam Therapeutics Inc. | $3.0B | 13 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%